Oral KPV in Hyaluronic Acid Nanoparticles Eased Ulcerative Colitis and Lowered TNF-α in Mice
Background
Treating ulcerative colitis (UC) is challenging due to the adverse effects of systemic drugs and the difficulty of delivering therapies specifically to inflamed colon tissue. Current treatments often lack selectivity, leading to widespread side effects. The naturally occurring tripeptide Lysine-Proline-Valine (KPV) has shown promise for its ability to attenuate inflammatory responses directly in colonic cells. However, its therapeutic potential is limited by poor stability and delivery. This study explores a novel drug delivery system designed to overcome these hurdles by encapsulating KPV in a vehicle that can survive oral transit and selectively target the cells most relevant to UC pathology.
Study Design
Researchers developed a novel oral delivery system for the peptide KPV. They loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (HA-KPV-NPs), which were then encapsulated in a chitosan/alginate hydrogel. The physical properties of the nanoparticles were characterized, including particle size (∼272.3 nm) and zeta potential (∼-5.3 mV). The system was tested in a mouse model of ulcerative colitis. Mice were orally administered the HA-KPV-NP/hydrogel system. The control arm received a similar hydrogel system but with nanoparticles lacking the hyaluronic acid functionalization (KPV-NP/hydrogel). Therapeutic efficacy was evaluated by assessing mucosa damage and measuring the inflammatory cytokine TNF-α.
Results
The HA-KPV-NPs successfully targeted key cells involved in UC, including colonic epithelial cells and macrophages, and were found to be nontoxic and biocompatible. This targeted system exerted combined effects, both accelerating mucosal healing and alleviating inflammation. In the mouse model, the orally administered HA-KPV-NP/hydrogel system demonstrated superior therapeutic efficacy compared to the non-targeted KPV-NP/hydrogel control.
The HA-functionalized system exhibited a much stronger capacity to prevent mucosa damage and significantly downregulate the pro-inflammatory cytokine
TNF-α. This indicates that the hyaluronic acid coating was crucial for enabling the nanoparticles to be released in the colonic lumen, penetrate into the inflamed colitis tissues, and facilitate the internalization of KPV into target cells, thereby effectively alleviating the symptoms of ulcerative colitis.
Key Findings
- Hyaluronic acid-functionalized KPV nanoparticles (HA-KPV-NPs) had a particle size of approximately 272.3 nm.
- The nanoparticles exhibited a slightly negative zeta potential of approximately -5.3 mV.
- Oral administration of the HA-KPV-NP/hydrogel system showed a much stronger capacity to prevent mucosa damage compared to a non-targeted control.
- The targeted HA-KPV-NP system significantly downregulated the inflammatory cytokine TNF-α in a mouse model of ulcerative colitis.
- The system successfully mediated targeted delivery of KPV to colonic epithelial cells and macrophages.
Why It Matters
This study presents a sophisticated oral delivery strategy that could significantly improve the treatment of ulcerative colitis with peptides like KPV. For individuals using peptides for inflammatory bowel conditions, this highlights the critical importance of the delivery vehicle; simply taking KPV orally is unlikely to be effective. The hyaluronic acid coating acts as a targeting mechanism, a key innovation for localizing the therapeutic effect and minimizing systemic exposure. While this is a preclinical animal study, it provides a strong proof-of-concept for developing targeted, orally administered peptide therapies for UC. Future work would need to validate these findings in human clinical trials to establish a usable protocol, but it paves the way for more effective and safer gut-specific anti-inflammatory treatments.
ulcerative colitis
kpv
nanoparticles
drug delivery
oral administration
animal study
